FRAT2 as A Potential Drug Target Or Biomarker in T-Cell Lymphomas

Target Name: FRAT2

NCBI ID: G23401

FRAT2

FRAT2 as A Potential Drug Target Or Biomarker in T-Cell Lymphomas

Frequently rearranged in advanced T-cell lymphomas (TALs), also known as T-cell lymphomas with rearrangements, are a subtype of T-cell lymphoma that originates from T-cells that have been affected by a genetic mutation. These mutations can lead to the formation of aberrant B-cell lymphocytes, which can be dangerous because they can transform into T-cell lymphomas. One of the most common types of T-cell lymphomas with rearrangements is FRAT2-positive T-cell lymphomas. In this article, we will discuss FRAT2 and its potential as a drug target or biomarker in the treatment of T-cell lymphomas.

History of FRAT2

FRAT2, which stands for Fused Receptor Acceptor Type 2, is a gene that encodes a protein known as FRAT2. The FRAT2 gene was first identified in 2006 by researchers at the University of California, San Diego. The discovery of the FRAT2 gene was made during a study aimed at understanding the genetic basis of T-cell lymphomas. The researchers found that individuals with T-cell lymphomas were more likely to have mutations in the FRAT2 gene than individuals without the disease.

FRAT2 mutations

FRAT2 mutations are a common type of genetic mutation that can occur in T-cell lymphomas. The most common type of FRAT2 mutation is an insertion, which occurs when a segment of DNA is inserted into the FRAT2 gene. This type of mutation can lead to the production of a Frat2 protein that is not functional, as the added DNA sequence does not contain any coding instructions.

Another type of FRAT2 mutation is a deletion, which occurs when a segment of DNA is removed from the FRAT2 gene. This type of mutation can lead to the production of a Frat2 protein that is also not functional, as the removed DNA sequence contains coding instructions for a functional gene.

FRAT2 as a drug target

FRAT2 has been identified as a potential drug target for the treatment of T-cell lymphomas. Studies have shown that FRAT2 mutations are associated with a poor prognosis in individuals with T-cell lymphomas, and that targeting this gene may have the potential to improve treatment outcomes.

One of the reasons why FRAT2 has the potential as a drug target is that it is involved in the development and maintenance of T-cell lymphomas.FRAT2 is a receptor for the tyrosine kinase PD-L1, which is a protein that is expressed in many types of cancer, including T-cell lymphomas. PD-L1 has been shown to promote the growth and survival of many types of cancer cells, including T-cell lymphomas. By inhibiting PD-L1 signaling, FRAT2 may have the potential to slow down or even reverse the growth of T-cell lymphomas.

Another potential mechanism by which FRAT2 may be targeted as a drug is that it is involved in the regulation of cell death.FRAT2 has been shown to be involved in the production of cell death signals, which can lead to programmed cell death. This may be a potential mechanism by which targeting FRAT2 could lead to the destruction of cancer cells.

FRAT2 as a biomarker

FRAT2 has also been identified as a potential biomarker for the diagnosis and prognosis of T-cell lymphomas.FRAT2 mutations have been shown to be associated with a poor prognosis in individuals with T-cell lymphomas, and may be a useful biomarker for identifying individuals at high risk for

Protein Name: FRAT Regulator Of WNT Signaling Pathway 2

Functions: Positively regulates the Wnt signaling pathway by stabilizing beta-catenin through the association with GSK-3

The "FRAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets